基于微RNA的治疗药在肝细胞癌中的新兴作用
Abdulhakim Umar Toro1, Sudheesh K Shukla2, Parveen Bansal3
1Department of Biomedical Engineering, Shobhit institute of Engineering and Technology (Deemed to-be-University), Modipuram, Meerut, 250110, India.
Molecular biology reports
|July 7, 2023
概括
由于预后不佳,肝细胞癌 (HCC) 仍然是致命的. 微RNAs (miRNAs) 显示出作为诊断标记物和改善HCC存活率的新疗法具有前途.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 是一个遗传学.
背景情况:
- 肝细胞癌 (HCC) 是一种致命的恶性瘤,存活率低,治疗选择有限.
- 对于新型诊断标记物和HCC的创新治疗策略,有极大的需求.
- 微RNAs (miRNAs) 是一种非编码RNA类,涉及到各种细胞过程和癌症的发展.
研究的目的:
- 探索miRNAs在肝细胞癌 (HCC) 中的治疗潜力.
- 调查miRNAs作为生物标志物的作用,用于早期检测和治疗HCC.
- 了解miRNAs如何调节细胞分化,增殖和生存在HCC的背景下.
主要方法:
- 审查当前关于miRNA功能在HCC的研究.
- 分析miRNA在瘤发生和瘤抑制中的作用.
- 探索基于miRNA的诊断和治疗策略.
主要成果:
- miRNAs是细胞分化,增殖和生存的关键调节者.
- 根据他们的目标,miRNAs可以作为瘤基因或瘤抑制剂.
- 新出现的证据表明,miRNAs对HCC疗效有很大的潜力.
结论:
- miRNAs代表了开发HCC.有效的诊断标记物的有希望的途径.
- miRNAs为创新的治疗策略提供了潜力,以改善HCC患者的治疗结果.
- 进一步的研究是必不可少的,以充分阐明和利用miRNAs在HCC中的治疗能力.
相关概念视频
01:22MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
02:39lncRNA - Long Non-coding RNAs
8.7K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K